StockData
Anbio Biotechnology logo

Anbio Biotechnology (NNNN) shareholders

NNNNNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Số liệu tài chính tới năm tài chính 2025, năm kết thúc ngày Dec 31, 2025Last filing: 20-F on Apr 7, 2026Score 11/30
$3.65−0.23 (-5.93%)

Close on Nov 17, 2026Market cap $525.20MP/E 24.8Yield –

Ownership

Who owns Anbio Biotechnology's shares

Held by institutions
–
Shares held, 13F filers
Institutional holders
–
Net institutional buying
–
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares owned% of sharesLatest filing
Michael LauCEO––Apr 8, 2026
Chris TianCBO––Apr 8, 2026
Suki SongCFO––Apr 8, 2026
Michael W.C ZhangDirector––Jun 12, 2026
David H. HsuDirector––Jun 12, 2026
Cany XuDirector––Apr 8, 2026
Nancy HartzlerDirector––Apr 8, 2026

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of float
0.02%
0M shares short
Days to cover
1.0
At 0M shares a day
Change since last report
+7.0%
From 0M shares
Short volume, 20 days
49.2%
Of volume reported to FINRA

Shares sold short, last 12 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Anbio Biotechnology's stock actually held short. Settlement fails (shares not delivered on time) peaked at 14,800 shares on Sep 23, 2026 over the last 90 days.

See a number that looks wrong?